Navigation Links
Pharmacyclics Reports Second Quarter 2013 Results
Date:7/31/2013

eve that the expectations reflected in the forward-looking statements are reasonable, we cannot guarantee future results, performance or achievements and no assurance can be given that the actual results will be consistent with these forward-looking statements. For more information about the risks and uncertainties that may affect our results, please see the Risk Factors section of our filings with the Securities and Exchange Commission, including our transition report on Form 10-K for the six month period ended December 31, 2012 and quarterly reports on Form 10-Q. We do not intend to update any of the forward-looking statements after the date of this announcement to conform these statements to actual results, to changes in management's expectations or otherwise, except as may be required by law.

 

 Pharmacyclics, Inc.Condensed Consolidated Balance Sheets(unaudited; in thousands)Jun. 30,Dec. 31,20132012AssetsCash, cash equivalents and marketable securities 1$ 504,984$ 317,114Other current assets 248,16829,378Total current assets553,152346,492Property and equipment, net14,2176,403Other assets3,2762,234Total assets$ 570,645$ 355,129Liabilities and Stockholders' EquityDeferred revenue - current portion$
7,680$
8,139Other current liabilities44,69721,118Total current liabilities52,37729,257Deferred revenue - non-current portion55,60562,562Deferred rent800784Total liabilities108,78292,603Stockholders' equity461,863262,526Total liabilities and stockholders' equity$ 570,645$ 355,1291Marketable securities$   10,830$
9,6812As of June 30, 2013 and December 31, 2012, Other current assets includes $37.3 million and $26.6 million, respectively, due to the Company from Janssen under the collaboration and license agreement. Pharmacyclics, Inc.Condensed Consolidated Statements of Operations(unaudited; in thousands, except per share data) Three Months EndedSix Months EndedJun. 30, Jun. 30,
'/>"/>

SOURCE Pharmacyclics, Inc.
Copyright©2012 PR Newswire.
All rights reserved

Page: 1 2 3 4 5 6 7 8 9 10 11 12 13 14 15 16 17

Related medicine technology :

1. Pharmacyclics Announces Date of Financial Results for Second Quarter Ended June 30, 2013 and Conference Call
2. Pharmacyclics Reports First Quarter 2013 Results
3. Pharmacyclics Announces Date of Financial Results for Three Months Ended March 31, 2013 and Conference Call
4. Pharmacyclics Triggers Fourth Milestone Payment for Enrollment of 5th Patient in Frontline Phase III CLL Study
5. Pharmacyclics Announces Third Breakthrough Therapy Designation for Ibrutinib from the U.S. Food and Drug Administration
6. Pharmacyclics, Inc. Prices Public Offering of Common Stock
7. Pharmacyclics, Inc. Announces Proposed Public Offering of Common Stock
8. Pharmacyclics First to Announce Breakthrough Therapy Designation in Oncology from the U.S. Food and Drug Administration
9. Pharmacyclics Announces Date of Financial Results for Three and Six Months Ended December 31, 2012 and Conference Call
10. Pharmacyclics Reports Fourth Quarter and Full Year Fiscal 2012 Financial Results and Recent Developments
11. Pharmacyclics Announces Oral Presentations of Ibrutinib (PCI-32765) at the 17th Congress of the European Hematology Association
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:10/31/2014)... 30, 2014 ... addition of the  "Process Validation in the US ...      (Logo: http://photos.prnewswire.com/prnh/20130307/600769) , ,Key topics ... Based Approach to Process Validation for Pharmaceutical and ... FDA Process Validation Guidance EU ...
(Date:10/31/2014)... 31, 2014  Isis Pharmaceuticals, Inc. (NASDAQ: ... , Isis Pharmaceuticals, Third Quarter 2014 Financial Results ... at 11:30 a.m. ET / 8:30 a.m. PTWhere: ... Internet. Simply log onto our website listed above. If ... a replay of the webcast will be available for ...
(Date:10/31/2014)... Ill., Oct. 31, 2014  AbbVie (NYSE: ... the third quarter ended Sept. 30, 2014. ... performance of our business with double-digit growth from ... business grew nearly 14 percent in the quarter ... chief executive officer, AbbVie.  "We exceeded our outlook ...
Breaking Medicine Technology:Process Validation in the US and EU (Workshop, London) 2Process Validation in the US and EU (Workshop, London) 3Process Validation in the US and EU (Workshop, London) 4Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 2Webcast Alert: Isis Pharmaceuticals' Third Quarter 2014 Financial Results Conference Call 3AbbVie Reports Third-Quarter 2014 Financial Results 2AbbVie Reports Third-Quarter 2014 Financial Results 3AbbVie Reports Third-Quarter 2014 Financial Results 4AbbVie Reports Third-Quarter 2014 Financial Results 5AbbVie Reports Third-Quarter 2014 Financial Results 6AbbVie Reports Third-Quarter 2014 Financial Results 7AbbVie Reports Third-Quarter 2014 Financial Results 8AbbVie Reports Third-Quarter 2014 Financial Results 9AbbVie Reports Third-Quarter 2014 Financial Results 10AbbVie Reports Third-Quarter 2014 Financial Results 11AbbVie Reports Third-Quarter 2014 Financial Results 12AbbVie Reports Third-Quarter 2014 Financial Results 13AbbVie Reports Third-Quarter 2014 Financial Results 14AbbVie Reports Third-Quarter 2014 Financial Results 15AbbVie Reports Third-Quarter 2014 Financial Results 16AbbVie Reports Third-Quarter 2014 Financial Results 17AbbVie Reports Third-Quarter 2014 Financial Results 18AbbVie Reports Third-Quarter 2014 Financial Results 19AbbVie Reports Third-Quarter 2014 Financial Results 20AbbVie Reports Third-Quarter 2014 Financial Results 21AbbVie Reports Third-Quarter 2014 Financial Results 22AbbVie Reports Third-Quarter 2014 Financial Results 23AbbVie Reports Third-Quarter 2014 Financial Results 24
(Date:10/31/2014)... cell division is central to life. The last stage, ... fascinated scientists since the dawn of cell biology in ... been notoriously difficult to study this final step, when ... two. , The name given to this process by ... captures the sense of a highly active and organized ...
(Date:10/31/2014)... of its kind, Rice University researchers have mapped how ... cells to become metastatic. The research reveals a common ... both migrate and form new tumors. Researchers say the ... interfere with the genetic switches that cancer must flip ... cells -- two of the main players in cancer ...
(Date:10/31/2014)... — A team from the Broad Institute, the ... California, Santa Cruz, was awarded one of three ... contracts with the goal of building a system ... Genome Atlas (TCGA) and other datasets by co-locating ... one cloud environment. This co-location will enable researchers ...
(Date:10/31/2014)... Daily Gossip writes in its Xtreme Fat ... the fastest fat loss program ever developed. It promises to ... , There is no wonder after all that this has ... The new nutrition and workout fat loss program was created ... , According to the author of this fat loss system, ...
(Date:10/31/2014)... October 31, 2014 This Method ... amazing health effects for practitioners. , The ... Doctor of Science and Movement specializing in physical ... to pelvic floor reeducation that traditional abdominal exercises ... Diastasis Recti, Prolepses, etc. , The Hipopressives exercises ...
Breaking Medicine News(10 mins):Health News:Cell division, minus the cells 2Health News:Cell division, minus the cells 3Health News:Decoding the emergence of metastatic cancer stem cells 2Health News:Decoding the emergence of metastatic cancer stem cells 3Health News:Broad Institute, Univ. of California team awarded NCI Cancer Genomics Cloud Pilot contract 2Health News:Broad Institute, Univ. of California team awarded NCI Cancer Genomics Cloud Pilot contract 3Health News:Xtreme Fat Loss Diet Review Reveals How to Transform Your Body in 25 Days 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 2Health News:Super Models and European Celebrities’ Secret Flat Tummy System Comes to America 3
... Over Q1 2008VANCOUVER, April 20 /PRNewswire-FirstCall/ - Response ... preliminary unaudited revenues for the three-month period ended ... to approximately $2.526 million compared to $1.173 million ... the highest revenues for any quarter in the ...
... Intervention Will Retain Decision Resources, Clinical Gold Standard ... from Decision ResourcesWALTHAM, Mass., April 20 Decision ... advisory firms for pharmaceutical and healthcare issues, finds ... mortality as the attribute that most influences their ...
... Mix Featuring Arthur and Friends , BURLINGTON, Mass. ... Cherrybrook Kitchen, the brand known for allergy-friendly desserts and ... Arthur, the award-winning PBS character whose TV show entertains ... challenges, lessons and obstacles of growing up. Launched in ...
... largest Italian American Service Organization in the United States, ... Awardees will be honored at the 87th Annual UNICO ... Americanism Award: Grand Order Filippo Mazzei ... of the Adopt a Soldier Platoon Cianci Humanitarian ...
... Leukemia & Lymphoma SocietyWHITE PLAINS, N.Y., April 20 For ... perform on behalf of their children and other loved ones ... special to pay tribute to mothers.Consider the heroic gesture performed ... more terrifying for a mother than to watch helplessly as ...
... To Sleep products so much, we bought the company"MILWAUKEE, ... today that ICP has acquired Scent To Sleep - ... a revolutionary All Natural Non-Drowsy Sleep Mist ( www.ScentToSleep.com ... To Sleep products so much, we bought the company. ...
Cached Medicine News:Health News:Response Biomedical Corporation Delivers Record Preliminary Revenues in First Quarter 2Health News:Response Biomedical Corporation Delivers Record Preliminary Revenues in First Quarter 3Health News:Response Biomedical Corporation Delivers Record Preliminary Revenues in First Quarter 4Health News:For Reducing Mortality, Current and Emerging Therapies Have No Advantage Over Carvedilol in the Treatment of Coronary Heart Disease (Stable Angina) 2Health News:For Reducing Mortality, Current and Emerging Therapies Have No Advantage Over Carvedilol in the Treatment of Coronary Heart Disease (Stable Angina) 3Health News:Cherrybrook Kitchen Announces New Partnership With Arthur 2Health News:Cherrybrook Kitchen Announces New Partnership With Arthur 3Health News:UNICO National Announces 2009 Award Winners 2Health News:UNICO National Announces 2009 Award Winners 3Health News:This Mother's Day Celebrate a Mother's Love 2Health News:Scent To Sleep All Natural Non-Drowsy Sleep Mist Acquired by Innovative Custom Products, Inc. (ICP) 2
... Increase profitability by ... with simple test,sequences ... administered by ancillary ... than 5 minutes. ...
Holladay Contract Acuity Test provides a more sensitive evaluation for testing visual functions than standard acuity charts....
Vectograms are the standard for vision training. They are available in fixed or variable,styles to accommodate unlimited base-in and base-out training. Each vectogram,includes one pair,of standard 3-...
... Designed to Meet All ... Binocular Cross Cylinder Horizontal and ... Associated Phoria, Binocular Visual Acuity ... Range Monocular Cross Cylinder, Random ...
Medicine Products: